BioRestorative Therapies (PK) Stock Price

0.00 (0.0%)
Volume 0.00
Bid Price 0.0028
Ask Price 0.0033
News -
Day High


52 Week Range


Day Low
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
BioRestorative Therapies Inc (PK) BRTX OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.0033 19:00:00
Open Price Low Price High Price Close Price Prev Close
0.0033 0.0033
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.0033 USD


Draw Mode:

BioRestorative Therapies Inc (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 11.06M 3.35B 6.98M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
122.34k $ - - - -

more financials information »

BioRestorative Therapies (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BRTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.0050.00670.00230.003965429,326,286-0.0017-34.0%
1 Year0.0120.0330.00230.009043233,801,865-0.0087-72.5%
3 Years0.6650.910.00010.007437225,047,754-0.6617-99.5%
5 Years4.205.010.00010.009036213,923,370-4.20-99.92%

BioRestorative Therapies (PK) Description

We develop therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs are: -- Disc/Spine Program (brtxDISCTM): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous cultured mesenchymal stem cells collected from bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. -- Metabolic Program (ThermoStem): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.